Floatz logo

Elotuzumab

Smoldering Multiple Myeloma

Dana-Farber Cancer Institutemonoclonal_antibodyPhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Smoldering Multiple Myeloma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Regeneron Pharmaceuticals
Phase 3BB
FILGRASTIM
Regeneron Pharmaceuticals
Phase 3BB
cc-5013
Irene Ghobrial, MD
Phase 3BB
Linvoseltamab
Regeneron Pharmaceuticals
Phase 3BB
DARATUMUMAB
Regeneron Pharmaceuticals
Phase 3BB

View all 48 →

Same molecule, other indications

Elotuzumab is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
64 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
B
Indicative ·
56 / 100
View asset →
plasma cell leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →